Clinical trial
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and…
NCT00272779 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00272779 |
|---|---|
| Title | BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada |
| Official title | A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV |
| Enrollment | 1,057 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | Jan 9, 2006 |
| Last update posted | May 9, 2011 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, France, Germany and 17 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: